PLX Protalix BioTherapeutics Inc
Price (delayed)
$2.96
Market cap
$230.98M
P/E Ratio
74
Dividend/share
N/A
EPS
$0.04
Enterprise value
$216.74M
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®. Protalix was the first company to
Highlights
PLX's debt has plunged by 79% YoY and by 2.8% from the previous quarter
Protalix BioTherapeutics's quick ratio has increased by 35% YoY and by 20% QoQ
PLX's net income has soared by 131% since the previous quarter but it has dropped by 65% year-on-year
PLX's EPS has surged by 127% since the previous quarter but it has dropped by 67% year-on-year
Key stats
What are the main financial stats of PLX
Market
Valuations
Earnings
Shares outstanding
78.03M
Market cap
$230.98M
Enterprise value
$216.74M
Price to earnings (P/E)
74
Price to book (P/B)
5.04
Price to sales (P/S)
4.02
EV/EBIT
41.55
EV/EBITDA
33.24
EV/Sales
4.06
Revenue
$53.4M
Gross profit
$29.08M
Operating income
$3.92M
Net income
$2.93M
EBIT
$5.22M
EBITDA
$6.52M
Free cash flow
$7.4M
Per share
Balance sheet
Liquidity
EPS
$0.04
EPS diluted
$0.04
Free cash flow per share
$0.1
Book value per share
$0.59
Revenue per share
$0.74
TBVPS
$1.01
Total assets
$73.42M
Total liabilities
$30.21M
Debt
$5.53M
Equity
$43.21M
Working capital
$34.46M
Debt to equity
0.13
Current ratio
2.34
Quick ratio
1.47
Net debt/EBITDA
-2.18
Margins
Efficiency
Dividend
EBITDA margin
12.2%
Gross margin
54.5%
Net margin
5.5%
Operating margin
7.3%
Return on assets
3.7%
Return on equity
8.8%
Return on invested capital
17.4%
Return on capital employed
10.9%
Return on sales
9.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PLX stock price
How has the Protalix BioTherapeutics stock price performed over time
Intraday
12.55%
1 week
13.85%
1 month
18.88%
1 year
146.67%
YTD
57.45%
QTD
15.63%
Financial performance
How have Protalix BioTherapeutics's revenue and profit performed over time
Revenue
$53.4M
Gross profit
$29.08M
Operating income
$3.92M
Net income
$2.93M
Gross margin
54.5%
Net margin
5.5%
Protalix BioTherapeutics's operating income has surged by 144% QoQ but it has shrunk by 63% YoY
The operating margin has soared by 137% from the previous quarter but it has plunged by 54% YoY
PLX's net income has soared by 131% since the previous quarter but it has dropped by 65% year-on-year
PLX's net margin has soared by 126% from the previous quarter but it has plunged by 57% YoY
Growth
What is Protalix BioTherapeutics's growth rate over time
Valuation
What is Protalix BioTherapeutics stock price valuation
P/E
74
P/B
5.04
P/S
4.02
EV/EBIT
41.55
EV/EBITDA
33.24
EV/Sales
4.06
PLX's EPS has surged by 127% since the previous quarter but it has dropped by 67% year-on-year
PLX's P/B is 74% above its last 4 quarters average of 2.9
Protalix BioTherapeutics's equity has increased by 33% QoQ and by 29% YoY
PLX's price to sales (P/S) is 123% higher than its 5-year quarterly average of 1.8 and 101% higher than its last 4 quarters average of 2.0
Protalix BioTherapeutics's revenue has decreased by 18% YoY but it has increased by 17% from the previous quarter
Efficiency
How efficient is Protalix BioTherapeutics business performance
The return on invested capital has surged by 172% since the previous quarter but it has declined by 37% year-on-year
PLX's return on sales has surged by 158% since the previous quarter but it is down by 45% year-on-year
The ROA has soared by 132% from the previous quarter but it has plunged by 64% YoY
Protalix BioTherapeutics's return on equity has surged by 128% QoQ but it has shrunk by 70% YoY
Dividends
What is PLX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PLX.
Financial health
How did Protalix BioTherapeutics financials performed over time
PLX's total assets is 143% greater than its total liabilities
The company's current ratio has surged by 52% YoY and by 18% QoQ
The total liabilities has decreased by 41% YoY but it has increased by 3.7% from the previous quarter
PLX's debt is 87% less than its equity
The debt to equity has dropped by 83% year-on-year and by 28% since the previous quarter
PLX's debt has plunged by 79% YoY and by 2.8% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.